← Leaderboards
Sanjeevani Arora
Research Inst Of Fox Chase Can Ctr
$691,376
Attributed
$1,382,752
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $470K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,382,752 · 2
By mechanism
UH3$870,915 · 1
UH2$511,837 · 1
Top collaborators
- Joshua E. Meyer4 shared
Most similar at Research Inst Of Fox Chase Can Ctr
Same institution · by research overlap
- Joshua E. Meyer$691,376
- Philip Abbosh$2,447,546
Others in their field
Other Rising Stars on “Academic Medical Centers”
- Richard Smith · Medical Device Innovation Consortium$42,211,350
- Sabrina Paganoni · Massachusetts General Hospital$11,004,714
- Suma Babu · Massachusetts General Hospital$11,004,714
- Michael Hogarth · University Of California, San Diego$9,300,393
- Nancy Jean Sullivan · Boston University Medical Campus$7,541,758
- Jennifer L. Kraschnewski · Pennsylvania State Univ Hershey Med Ctr$6,438,530
Research focus
Academic Medical CentersAssay DevelopmentAdjuvantBasic ScienceBiological MarkersBiological Specimen BanksBiomarker ValidationBlindedBloodBlood SpecimenCalibrationCancer CenterCancer Clinical TrialCancer PatientCandidate MarkerCandidate ValidationCell ImmortalizationCell LineCellsCharacteristicsChek1 GeneChek2 GeneChemoradiationChemotherapy-Oncologic Procedure
Grant awards (4)
Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer$470,000
UH3 · FY2025 · CA · contact PI
Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer$400,915
UH3 · FY2024 · CA · contact PI
Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer$253,008
UH2 · FY2023 · CA · contact PI
Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer$258,829
UH2 · FY2022 · CA · contact PI